Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)

The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS)


Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Estimated Enrollment: 750
Study Start Date: May 2011
Estimated Study Completion Date: July 2019
Estimated Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)

Arms:
- Active Comparator: Lenalidomide + Dexamethasone
- Experimental: Lenalidomide + Dexamethasone + Elotuzumab